What Makes Retatrutide Different?

Retatrutide is the most recent generation of incretin-based research compounds, extending the dual GIP/GLP-1 agonism of tirzepatide to include a third target: the glucagon receptor (GCGR). This triple mechanism distinguishes it from all previous GLP-1 class peptides and has generated significant research interest in metabolic biology.

Compound	Targets	Generation
Semaglutide	GLP-1R	1st gen monoagonist
Tirzepatide	GLP-1R + GIPR	2nd gen dual agonist
Retatrutide	GLP-1R + GIPR + GCGR	3rd gen triple agonist

The addition of GCGR activity is hypothesized to increase hepatic glucose output regulation and energy expenditure beyond what GLP-1 and GIP dual agonism achieves. Retatrutide is currently in Phase II/III clinical trials. Its research profile is the most expansive of the three generations. See full comparison: Semaglutide vs Tirzepatide vs Retatrutide →

Frequently Asked Questions

Can I buy retatrutide in Canada for research?

Yes. TrueCanPeptides supplies retatrutide as a research compound for qualified laboratory use, shipped domestically within Canada. Not for human administration.

What sizes do you offer for retatrutide?

Retatrutide is available in 10mg and 20mg vials. Both are available individually or as a 10-pack with a volume discount.

How does retatrutide compare to semaglutide?

Semaglutide targets only GLP-1R. Retatrutide adds GIP receptor and glucagon receptor co-agonism, making it a third-generation triple agonist. Clinical trial data suggests a more pronounced effect profile. See the full receptor comparison →

Related: Retatrutide 10mg | Retatrutide 20mg | What Is Retatrutide? | Sema vs Tirze vs Reta

Retatrutide supplied for qualified in vitro laboratory research only. Not for human or animal administration. Not evaluated by Health Canada. Research use only.